AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01806298
Drug: Saizen® solution for injection (referred as Saizen®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saizen® solution for injection will be administered subcutaneously daily for 39 weeks according to locally approved product labeling for the currently marketed formulation of Saizen®.
Trial: NCT01599234
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contains peppermint oil flavouring, 0.05%(v/v); quinoline yellow,0.005% (w/v) and sunset yellow, 0.0025% (w/v) colourants, in a and ethanol:propylene glycol (50:50) excipient.
Trial: NCT00754819
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule daily
Trial: NCT01442155
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered according to the Summary of Product Characteristics.
Trial: NCT01267734
Drug: Triple anti-platelet therapy (TAT)
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg Aspirin QD + 75mg Clopidogrel QD + 100mg Cilostazol BID for 1 month
Trial: NCT02603614
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo control
Trial: NCT00679315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet to be taken daily after a meal before bedtime for 8 weeks.
Trial: NCT03116893
Drug: BI 685509 After Standardised Breakfast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat high calorie breakfast
Trial: NCT01125683
Drug: AZD1446
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, oral single and multiple dose
Trial: NCT01125683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, oral and single dose
Trial: NCT00292266
Drug: Rebif®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebif® injection will be administered subcutaneously at a dose of 44 mcg, three times per week, up to 72 weeks.
Trial: NCT00292266
Drug: Avonex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avonex® injection will be administered intramuscularly at a dose of 30 mcg, once weekly, up to 72 weeks.
Trial: NCT01679860
Drug: Clin B (CHOP- CAMPATH) Chemo-immunotherapy
RxNorm normalized name: DISPENSING PIN,CHEMO B BRAUN #412014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clin B:~* CHOP-Campath (CHOP-C) for 6 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO from day +1 to day +5¸ Campath-1H (alemtuzumab) 3-10mg IV on days - 1 and 0 ( first CHOP-C course) or 10mg SC on day 0 (for the following 5 C-CHOP courses). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on day +1 of each CHOP-C course.
Trial: NCT01083576
Drug: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical application to CL lesions once daily for 20 days
Trial: NCT01083576
Drug: Paromomycin Alone Cream (15% paromomycin topical cream)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical application to CL lesions once daily for 20 days
Trial: NCT02459353
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04002544
Drug: NTG patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A half-NTG patch (dose calculated at 5-12.5 mcg/kg/hr) will be applied to patients at the site of radial pulsation one hour before induction of anesthesia. The NTG patch will be applied to the right upper in half of the patients and will be applied to the left upper limb in the other half
Trial: NCT04043026
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any statin therapy
Trial: NCT00482092
Drug: Prochymal®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochymal® IV infusion
Trial: NCT00482092
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochymal® Placebo-matching IV infusion
Trial: NCT00694993
Drug: GSK1004723
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1004723 will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
Trial: NCT00694993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
Trial: NCT00486200
Drug: ASP2151
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration.
Trial: NCT00486200
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of placebo.
Trial: NCT03230097
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo matching 50 milligrams BI 409306, as a film-coated tablet, orally twice a day at approximately the same time every day in the morning and in the evening (approximately 12 hours apart) with or without food for 52 weeks.
Trial: NCT00577681
Drug: Antiretroviral Therapy (ART)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Either episodic ART or continuous ART. All groups will have plasma specimens taken to compare changes in lipoprotein particle sizes and numbers and changes in inflammatory and coagulation markers.
Trial: NCT00509015
Drug: placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 days of lactose tablets (160mg) albochin
Trial: NCT01312272
Drug: Inactive placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo nasal spray will be prepared identically to the oxytocin nasal spray except lacking oxytocin. Its ingredients are mannitol, glycerin, and preserved water. It will be administered at 5 sprays to each nostril, one time.
Trial: NCT03081169
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The same drugs and dosages will be used in both groups, with only the timing being different
Trial: NCT04443608
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Powder will be mixed with a liquid (water, apple or cranberry juice) and given to patient to drink
Trial: NCT02198352
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03374397
Drug: Surgiguard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemostasis with Surgiguard during laparoscopic unilateral ovarian cystectomy
Trial: NCT00119626
Drug: NXY-059
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01292616
Drug: therapy with disease-modifying anti rheumatic drugs (DMARD)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMARD drug and dosage is chosen by the treating physician without restriction by the study
Trial: NCT01013376
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle
Trial: NCT01084369
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NEBIDO ampoules containing a solution for injection of 1000mg/4ml of testosterone undecanoate. NEBIDO injection 1000mg/4ml will be given at baseline, 6 weeks, 18 weeks, 30 weeks, 42 and 54 weeks. Levitra will be given to those patients with erectile dysfunction for 2 weeks in addition to Nebido.~Concomitant medication deemed necessary by the investigator as part of the routine clinical management will be permissable.
Trial: NCT00428311
Drug: Ethynyl-estradiol plus cyproterone acetate
RxNorm normalized name: Ethynyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03198117
Drug: Huaier Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a Chinese traditional medicine
Trial: NCT03782792
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion
Trial: NCT02073552
Drug: Macrogol 3350 plus ascorbic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: - Macrogol 3350 plus ascorbic acid: 4 envelopes, 2 containing 112 g polyethylene glycol and electrolytes and 2 with 2 g of ascorbic acid. The properties of the polyethylene glycol are the same as those mentioned previously, while ascorbic acid generates an osmotic gradient potentiating the effect of polyethylene glycol. It is used routinely as a bowel prep. Participants will divide the doses in 2 liters of water taking half the day before (112 g of PEG and an 11 g of ascorbic acid) the examination at 20.00 h and the other half at 6.00 pm on the day of the examination
Trial: NCT01180062
Drug: Arm 2
RxNorm normalized name: Surgitube Arm 2 5/8x50"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.
Trial: NCT01280175
Drug: pMDI standard actuator
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01201018
Drug: Oshadi D, Oshadi R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT02866552
Drug: Ringer lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02706691
Drug: BGJ398
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by mouth (oral)
Trial: NCT01427686
Drug: Dopamine
RxNorm normalized name: Dopamine
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Start Dopamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dobutamine.
Trial: NCT00772291
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo drug during 8 weeks
Trial: NCT00217295
Drug: Avonex and Topamax
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01619423
Drug: Placebo (0,9% NaCl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0,9% NaCl) is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
Trial: NCT04022993
Drug: Lantus Solostar, 100 Units/mL Subcutaneous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses
Trial: NCT04022993
Drug: Insulin RinGlar, 100 Units/mL Subcutaneous Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 weeks of glucose-level based dose titration, 22 weeks of treatment with stable doses
Trial: NCT00113984
Drug: MDX-010
RxNorm normalized name: hydrocortisone acetate Topical Gel [Cortisil MDX]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04343547
Drug: DWP16001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, once daily single dose
Trial: NCT04343547
Drug: DWC202001+DWC202002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, multiple doses of DWC202001 and DWC202002 in combination
Trial: NCT04343547
Drug: DWP16001+DWC202001+DWC202002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, DWP16001 , DWC202001 and DWC202002 in combination
Trial: NCT02521610
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive the placebo equivalent to RG7625 once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
Trial: NCT02521610
Drug: RG7625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive RG7625 as oral capsules once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
Trial: NCT01007097
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-875 placebo-matching tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
Trial: NCT04343963
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet P.O. once per day for 14 days
Trial: NCT03925974
Drug: KN026 10 mg/kg QW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg QW as safety run-in dosage
Trial: NCT03925974
Drug: KN026 20 mg/kg Q2W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg Q2W as target dosage
Trial: NCT03925974
Drug: KN026 30 mg/kg Q3W
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg Q3W as another target dosage
Trial: NCT00851747
Drug: Phosphatidylcholine Deoxycholate
RxNorm normalized name: deoxycholate
DrugBank: Deoxycholic acid (DB03619)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
Trial: NCT01352858
Drug: TolDC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolerogenic dendritic cells (TolDC), derived ex vivo from autologous monocytes, administered arthroscopically into an inflamed knee following saline irrigation.
Trial: NCT01352858
Drug: Arthroscopy & saline irrigation alone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04176757
Drug: ZN-c5
RxNorm normalized name: dipentaerythrityl hexa C5-10 acid esters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZN-c5 study drug to be administered orally daily
Trial: NCT04412824
Drug: Intravenous blood draw
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session
Trial: NCT01854710
Drug: Inhaled Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staccato placebo via inhalation x 2 at 2 hours apart
Trial: NCT01854710
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule identical in appearance to moxifloxacin
Trial: NCT03951571
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before breakfast, take an placebo once a day, 1 pill at a time. Continuous oral administration for two weeks and stop for one week. Three weeks (21 days) for a treatment cycle. The total treatment cycles is six.
Trial: NCT00064116
Drug: CHOP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6
Trial: NCT02407353
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo which will be dosed as oral suspension, single doses to match PF-06648671
Trial: NCT00967135
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral placebo twice daily for 5 consecutive days.
Trial: NCT04149691
Drug: CPL304110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPL304110 is to be administered orally as hard gelatine capsules once daily in 28-day cycles.
Trial: NCT00834444
Drug: Famvir® 500 mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 500 mg, single-dose fasting
Trial: NCT04418167
Drug: JSI-1187
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JSI-1187 capsules for oral administration
Trial: NCT02890069
Drug: LCL161
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02817100
Drug: BAY1817080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study part 1: Escalating doses of BAY1817080; single dose administration; solid dosage form (redosing of BAY1817080 at dose group 1 and 2 together with itraconazole; redosing of BAY1817080 at dose group 4 together with food \[American breakfast\]) Study part 2: Escalating doses of BAY1817080; single dose administration together with an American breakfast; solid dosage form (redosing of BAY1817080 at dose group 1, 2 and 4 together with food \[Continental breakfast\])
Trial: NCT02890069
Drug: QBM076
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02890069
Drug: HDM201
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01496495
Drug: ARRY-614, p38/Tie2 inhibitor; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule
Trial: NCT02817100
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study part 1: Escalating doses of respective placebos; single dose administration; solid dosage form (redosing of placebo at dose group 1 and 2 together with itraconazole; redosing of placebo at dose group 4 together with food \[American breakfast\]) Study part 2: Escalating doses of respective placebos; single dose administration together with an American breakfast; solid dosage form (redosing of placebo at dose group 1, 2 and together with food \[Continental breakfast\])
Trial: NCT01614223
Drug: Corticosteroid (celestone) injection
RxNorm normalized name: Celestone Soluspan Injectable Product
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation of the blood sample is identical for patients in this group except that the blood sample will ultimately be discarded instead of injected. The syringe is blinded with opaque tape making it identical to the ACP group syringe and injected into the torn area of the tendon.
Trial: NCT02936830
Drug: 15% Nanohydroxyapetite paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15% nanohydoxyapetite paste without potassium nitrate or fluoride applied on the dentin by the dentist
Trial: NCT02300688
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of 1 time administration of the test drug (Treatment A)
Trial: NCT02300688
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administration of 1 time administration of the reference drug (Treatment B)
Trial: NCT00669162
Drug: Casodex and Zoladex (or Lupron)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casodex 50 mg po daily for 6 months, and Zoladex 10.8 mg sc q 3 mos x 2 (or Lupron 22.5 mg im q 3 mos x 2)
Trial: NCT04983160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01634139
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 actuations once daily in the evening
Trial: NCT00250263
Drug: (agent for immunotherapy) Staloral
RxNorm normalized name: aspirin / hydrocodone bitartrate Oral Tablet [Alor]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy agent for sublingual daily use. First week (vial containing the concentration 10 IR/ml) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing the concentration 300 IR/ml) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily~The first year will be followed by a second year open label period (optional)- 8 pressures daily
Trial: NCT00250263
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for sublingual use. Same schedule used for the intervention ACTIVE group.~First week (vial containing placebo) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures~Second week (300 IR/ml) (vial containing placebo) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures~Maintenance phase Day 12 to 364 - 8 pressures daily
Trial: NCT00862095
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Every month for 3 months
Trial: NCT01906008
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for 4 months beginning at chemotherapy initiation.
Trial: NCT01906008
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo by mouth for the first day of chemotherapy, then 1 dose every 12 hours for 4 months beginning at chemotherapy initiation.
Trial: NCT00740831
Drug: PGL4001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT01830972
Drug: SA-IR 500 mg
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsules
Trial: NCT02319993
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1/10 TIAN WANG BU XIN DAN assigned to placebo (n =32) and were instructed to take 6 gm 2 times per day of placebo for a period of 4 weeks.
Trial: NCT03214588
Drug: TAK-831 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-831 placebo matching tablets
Trial: NCT02020330
Drug: Artemether-lumefantrine 3 days
RxNorm normalized name: Artemether/lumefantrine
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet contains 20mg artemether and 120mg lumefantrine. The standard regimen is twice daily for 3 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 3 days arm.
Trial: NCT02620137
Drug: Multicentrum® (Pfizer, Spain) 3 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 3 months
Trial: NCT02620137
Drug: Multicentrum® (Pfizer, Spain) 12 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 12 months